Tourmaline Bio, Inc. (TRML)
Tourmaline Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $47.98, up 0.00% on the session, giving a market capitalisation of $1.23B. On trailing twelve-month figures it carries a trailing P/E of -26.80, a net margin of 0.0%. Its beta of 1.58 implies it has historically moved more than the broad market.
Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED). Established in 2021, this enterprise is headquartered in New York, New York.
Tourmaline Bio, Inc. is most often compared with the following Healthcare names: